A novel synbiotic (SCM06) for anxiety and sensory hyperresponsiveness in children with autism spectrum disorder: an open-label pilot study
Anxiety and sensory hyperresponsiveness are common in children with autism spectrum disorder (ASD), but effective treatments are lacking. Targeting the microbiota-gut-brain axis is a promising strategy. This open-label pilot study (ClinicalTrials.gov ID: NCT06126185) evaluated the safety, tolerability, and efficacy of SCM06, a novel synbiotic that regulates GABA levels and immune function, in 30 children with ASD.